what are next steps for this mi patient according to standard indian guidelines
Reading File
Reading File
Running Command
Finding Sources
Searching the Web
CSI CARDIOLOGICAL SOCIETY INDIA guidelines STEMI NSTEMI ACS management 2024 2025
Running Command
post MI next steps management PCI angiography revascularization medications secondary prevention
Finding Sources
Running Command
Running Command
Running Command
Reading Web Page
PCI RCA total occlusion chronic total occlusion CTO revascularization DVD post STEMI IWMI secondary prevention medications next steps management India guidelines
Finding Sources
Searching PubMed
PCI chronic total occlusion RCA STEMI inferior wall secondary prevention India
Reading File
I have all the information needed. Here is the comprehensive clinical analysis and next-step recommendations.
Coronary Angiography Report - Yogesh Maganlal Barot (65M)
U.N. Mehta Institute of Cardiology & Research Center, Ahmedabad
Procedure Date: 04/06/2026 | Angio No.: C-11366
Angiographic Findings Summary
| Vessel | Finding |
|---|---|
| LMCA | Normal |
| LAD Ostium | 80% stenosis |
| Mid LAD | 70% stenosis |
| Distal LAD | 70% stenosis |
| LCX | Normal |
| RCA (Proximal) | 100% occlusion (Total) - receiving Grade II collaterals from LAD |
Final Diagnosis: HTN, IWMI (Established), CAD - Double Vessel Disease (DVD)
LV Function: Mild LV Dysfunction (mild LVD)
Treating Cardiologist's Advice: PCI to RCA
Next Steps - Per CSI (Cardiological Society of India) & Indian Guidelines
1. IMMEDIATE INTERVENTION: PCI to RCA (Chronic Total Occlusion - CTO PCI)
The treating cardiologist has already recommended PCI to RCA. This is appropriate because:
- The proximal RCA is 100% occluded with Grade II collaterals from LAD - this is a Chronic Total Occlusion (CTO)
- Established IWMI (Inferior Wall MI) - the RCA territory is viable given collateral supply
- Grade II collaterals suggest partial preservation - CTO-PCI can restore antegrade flow, reduce anginal burden, and improve LV function over time
- Per CSI STEMI guidelines and ESC 2023 ACS guidelines: complete revascularization is recommended in multivessel CAD post-MI, especially when the non-culprit vessel (here, both RCA and LAD) has significant disease
Important consideration: The LAD also has critical disease (80% ostial + 70% mid + 70% distal). The current advice is PCI to RCA only - the LAD disease will need to be discussed in a Heart Team meeting (Cardiology + Cardiac Surgery) given the complexity (multi-segment LAD disease + CTO RCA = complex DVD). CABG may be an option to consider.
2. STAGING STRATEGY FOR LAD REVASCULARIZATION
- After successful RCA CTO-PCI, reassess LAD territory with FFR (Fractional Flow Reserve) or iFR to confirm hemodynamic significance
- Ostial LAD 80% with multi-segment disease is high-risk for PCI (ostial lesions technically challenging; risk of plaque shift into LMCA)
- Heart Team discussion recommended per CSI guidelines before LAD intervention
- Options: staged PCI to LAD vs. CABG (especially given 3-segment LAD disease + HTN + mild LVD)
3. PRE-PROCEDURE PREPARATION (Before CTO-PCI)
- Dual antiplatelet therapy (DAPT): Aspirin 75-150 mg + Clopidogrel 75 mg/day (or Ticagrelor 90 mg BD) - should be on DAPT; ensure loading if not already loaded
- Statins: High-intensity - Rosuvastatin 20-40 mg or Atorvastatin 40-80 mg (LDL target <70 mg/dL per Indian guidelines, ideally <55 mg/dL)
- Beta-blocker: Metoprolol succinate (or bisoprolol) - for LV protection given mild LVD
- ACE inhibitor or ARB: Ramipril or Perindopril - mandatory given post-MI + mild LVD
- Control BP: Target <130/80 mmHg (HTN present)
- Renal function & eGFR check before contrast exposure (already used 60 mL contrast today)
- Hydration pre and post PCI to prevent contrast nephropathy
4. SECONDARY PREVENTION MEDICATIONS (Per CSI STEMI Position Statement)
The CSI guidelines mandate the following five core drugs post-STEMI, aimed at highest tolerated doses:
| Drug Class | Drug | Target/Notes |
|---|---|---|
| Antiplatelet 1 | Aspirin 75-150 mg OD | Lifelong |
| Antiplatelet 2 | Clopidogrel 75 mg OD or Ticagrelor 90 mg BD | Minimum 12 months post-PCI (DAPT) |
| Statin | Atorvastatin 40-80 mg or Rosuvastatin 20-40 mg | LDL <70 mg/dL (or <55 mg/dL if high-risk) |
| Beta-blocker | Metoprolol succinate 25-200 mg OD or Bisoprolol 2.5-10 mg OD | Especially with mild LVD |
| ACEI/ARB | Ramipril 2.5-10 mg OD or Perindopril 4-8 mg | Post-MI + LVD = mandatory |
Additional for HTN + Mild LVD:
- Consider aldosterone antagonist (Eplerenone or Spironolactone) if EF <40% after reassessment
- Nitrates (short-acting PRN or long-acting if angina persists)
5. CARDIAC REHABILITATION & LIFESTYLE
Per CSI STEMI guidelines (Section 11):
- Enroll in structured cardiac rehabilitation program
- Smoking cessation (if applicable)
- Dietary modification: Low sodium, low saturated fat, Mediterranean-type diet
- Physical activity: Graded exercise, walking program after PCI recovery
- Weight management if overweight
- Diabetes screening if not already done (65M, HTN - high T2DM risk)
- Psychosocial support - depression screening post-MI
6. FOLLOW-UP PLAN
| Timeframe | Action |
|---|---|
| 1-2 weeks post-PCI | Wound check (radial access site), medication tolerability review |
| 1 month | Lipid profile, renal function, BP review |
| 3 months | ECG, Echo to reassess LV function post-RCA revascularization |
| 6 months | Review DAPT, reassess LAD (FFR/iFR or repeat angio if symptomatic) |
| 12 months | Consider DAPT de-escalation if no events |
7. CLINICAL FLAGS IN THIS CASE
- Grade II collaterals to RCA from LAD - this makes the LAD the "life-sustaining" vessel. Any complication during LAD PCI could be catastrophic. Proceed with extreme caution on LAD; CTO-PCI of RCA first is the right sequence.
- Ostial LAD 80% - Ostial lesions carry risk of proximal edge dissection and LMCA involvement. Require experienced operator and likely drug-eluting stent (DES) with IVUS guidance.
- Mild LVD - Optimize GDMT (Guideline-Directed Medical Therapy) before and after PCI. Reassess EF post-revascularization at 3 months.
- 65 year old male with HTN - Screen for CKD (baseline creatinine/eGFR), peripheral vascular disease, and carotid disease as part of comprehensive vascular risk assessment.
In summary: The immediate next step is CTO-PCI to RCA as advised. This should be followed by Heart Team discussion regarding the complex LAD disease (3-segment, ostial origin), concurrent optimization of all five guideline-mandated secondary prevention medications, and enrolment in cardiac rehabilitation. The CSI STEMI position statement and Indian MoHFW cardiovascular guidelines both emphasize that secondary prevention starting in-hospital is as important as the revascularization procedure itself.
This is a shared conversation. Sign in to Orris to start your own chat.